ALK-Abelló A/S
ALK-B
Rangering i aksjer
#2354
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Aksjekurs
$37.76
Sist synkronisert: 2026-10-20
Markedsverdi
$8.38B
Endring (1 dag)
-0.08%
Endring (1 år)
14.34%
Land
DK
Handel ALK-Abelló A/S (ALK-B)
Kategori
Healthcare
Antall utestående aksjer for ALK-Abelló A/S (ALK-B)
Antall utestående aksjer per June 2026: 221.88M
Ifølge ALK-Abelló A/S sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 221.88M. Ved slutten av December 2023 hadde selskapet 221.15M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for ALK-Abelló A/S (ALK-B) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 221.88M | 0.25% |
| 2024 | 221.32M | 0.08% |
| 2023 | 221.15M | 0.29% |
| 2022 | 220.50M | 0.51% |
| 2021 | 219.39M | 0.49% |
| 2020 | 218.32M | 0.14% |
| 2019 | 218.01M | 0.31% |
| 2018 | 217.33M | 9.53% |
| 2017 | 198.43M | 1.07% |
| 2016 | 196.33M | 1.15% |
| 2015 | 194.09M | 0.46% |
| 2014 | 193.20M | 0.00% |
| 2013 | 193.20M | -0.87% |
| 2012 | 194.91M | -1.53% |
| 2011 | 197.94M | -0.14% |
| 2010 | 198.22M | -0.49% |
| 2009 | 199.19M | -0.34% |
| 2008 | 199.88M | -0.33% |
| 2007 | 200.53M | -0.74% |
| 2006 | 202.02M | 0.47% |
| 2005 | 201.07M | -0.60% |
| 2004 | 202.28M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 14.43% |
US
|
|
| 396.00M | 78.48% |
US
|
|
| 478.91M | 115.84% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -71.97% |
NL
|
